Here’s what Chromadex CEO Rob Fried said on a recent podcast about clinical studies looking at Nicotinamide Riboside “NR” (FAQs) (Reviews):

At the 19:50 mark of the video below:

“It’s difficult to say which one I’m most excited about.

There are several that we’re paying close attention to.

There’s a University of Washington study on cardiovascular inflammation (See HERE).

There’s a study in San Antonio being conducted on cognitive clarity or blood flow inside the brain (See HERE).

We’re excited about these brain related studies (See HERE, HERE, HERE, and HERE).

There’s a phase 2 clinical study on fatty liver going on right now (See HERE).

We have very very strong data in fact that the Turkey researcher who did the cocktail study on COVID also put out a study on fatty liver disease — non-alcoholic fatty liver disease — and showed a benefit there (See HERE).

So we’re very excited on these fatty liver studies that are ongoing that we think has a benefit.

There are several COVID studies that are underway that we’re interested in (HERE, HERE, HERE, and HERE) — not just for COVID per se — but what it implies for infectious diseases and viruses in general.

So there are a number that we’re keeping our eye on and are excited about.”

RELATED:

  • You can see a complete list of clinical studies on Nicotinamide Riboside (NR) HERE.
  • NR supplementation may have helped sufferers of these diseases & conditions (Consumer Reviews)
  • FAQs on taking NAD boosting vitamin supplement Nicotinamide Riboside (NR) can be found HERE.

FOLLOW us on Twitter @RaisingNAD